MDM2 and acute myeloid leukemia: Unfortunately, in a completed Phase III clinical trial (NCT02545283), the combination of the MDM2 inhibitor idasanutlin (RG-7388) and cytarabine did not improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) [200].